Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.37 |
| ▸ | FFAR3 | O14843 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.33 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.32 |
| ▸ | CTSD | P07339 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | POLA1 | P09884 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL555291 | 0.88 | APEX1 (0.39) | TSHRKDM4EALDH1A1CES2CES1 | |
| SCHEMBL554182 | 0.86 | AKR1B1 (0.43) | TSHRALDH1A1CES2CES1POLB | |
| SCHEMBL6877098 | 0.83 | HCAR2 (0.37) | TSHRHDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL7772525 | 0.83 | HCAR2 (0.37) | TSHRHDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL7771247 | 0.83 | KDM4E (0.43) | TSHRKDM4EFFAR3ALDH1A1EGLN1 | |
| SCHEMBL555080 | 0.83 | KDM4E (0.43) | TSHRKDM4EFFAR3ALDH1A1EGLN1 | |
| SCHEMBL7767062 | 0.83 | KDM4E (0.43) | TSHRKDM4EFFAR3ALDH1A1EGLN1 | |
| SCHEMBL6029952 | 0.81 | ALDH1A1 (0.48) | TSHRKDM4EALDH1A1 | |
| SCHEMBL6029955 | 0.81 | ALDH1A1 (0.48) | TSHRKDM4EALDH1A1 | |
| SCHEMBL9410921 | 0.80 | ALDH1A1 (0.39) | TSHRHDAC3HDAC1HDAC2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220105064-A1 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING A FUMARIC ACID ESTER | BIOGEN SWISS MFG GMBH (CH) | 2022-04-07 | — | — | US | claimed |
| US-20220079884-A1 | PHARMACEUTICAL FORMULATION COMPRISING ONE OR MORE FUMARIC ACID ESTERS IN AN EROSION MATRIX | BIOGEN SWISS MFG GMBH (CH) | 2022-03-17 | — | — | US | claimed |
| US-11229619-B2 | Controlled release pharmaceutical compositions comprising a fumaric acid ester | BIOGEN SWISS MANUFACTURING GMBH (CH) | 2022-01-25 | — | — | US | claimed |
| US-20180221284-A1 | PHARMACEUTICAL FORMULATION COMPRISING ONE OR MORE FUMARIC ACID ESTERS IN AN EROSION MATRIX | BIOGEN SWISS MANUFACTURING GMBH (CH) | 2018-08-09 | — | — | US | claimed |
| US-20150272894-A1 | PHARMACEUTICAL FORMULATION COMPRISING ONE OR MORE FUMARIC ACID ESTERS IN AN EROSION MATRIX | BIOGEN SWISS MANUFACTURING GMBH (CH) | 2015-10-01 | — | — | US | claimed |
| US-20130259906-A1 | PHARMACEUTICAL COMPOSITION COMPRISING ONE OR MORE FUMARIC ACID ESTERS | FORWARD PHARMA A/S (DK) | 2013-10-03 | — | — | US | claimed |
| US-20120034303-A1 | PHARMACEUTICAL FORMULATION COMPRISING ONE OR MORE FUMARIC ACID ESTERS IN AN EROSION MATRIX | FORWARD PHARMA A/S (DK) | 2012-02-09 | — | — | US | claimed |
| US-20120034274-A1 | PHARMACEUTICAL COMPOSITION COMPRISING ONE OR MORE FUMARIC ACID ESTERS | FORWARD PHARMA A/S (DK) | 2012-02-09 | — | — | US | claimed |
| EP-2379063-A1 | PHARMACEUTICAL FORMULATION COMPRISING ONE OR MORE FUMARIC ACID ESTERS IN AN EROSION MATRIX | Forward Pharma A/S (DK) | 2011-10-26 | — | — | EP | claimed |
| EP-2379062-A1 | PHARMACEUTICAL COMPOSITION COMPRISING ONE OR MORE FUMARIC ACID ESTERS | Forward Pharma A/S (DK) | 2011-10-26 | — | — | EP | claimed |
| WO-2010079222-A1 | PHARMACEUTICAL FORMULATION COMPRISING ONE OR MORE FUMARIC ACID ESTERS IN AN EROSION MATRIX | FORWARD PHARMA A/S (DK) | 2010-07-15 | — | — | WO | claimed |
| WO-2010079221-A1 | PHARMACEUTICAL COMPOSITION COMPRISING ONE OR MORE FUMARIC ACID ESTERS | FORWARD PHARMA A/S (DK) | 2010-07-15 | — | — | WO | claimed |
| US-20240240229-A1 | METHODS OF ADMINISTERING MONOMETHYL FUMARATE AND PRODRUGS THEREOF HAVING REDUCED SIDE EFFECTS | HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT | 2024-07-18 | — | — | US | disclosed |
| US-20220105064-A1 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING A FUMARIC ACID ESTER | BIOGEN SWISS MFG GMBH (CH) | 2022-04-07 | — | — | US | disclosed |
| US-20220079884-A1 | PHARMACEUTICAL FORMULATION COMPRISING ONE OR MORE FUMARIC ACID ESTERS IN AN EROSION MATRIX | BIOGEN SWISS MFG GMBH (CH) | 2022-03-17 | — | — | US | disclosed |
| US-11229619-B2 | Controlled release pharmaceutical compositions comprising a fumaric acid ester | BIOGEN SWISS MANUFACTURING GMBH (CH) | 2022-01-25 | — | — | US | disclosed |
| WO-2007006307-A2 | NOVEL SALTS OF FUMARIC ACID MONOALKYLESTERS AND THEIR PHARMACEUTICAL USE | ADITECH PHARMA AB (SE) | 2007-01-18 | — | — | WO | disclosed |
| WO-2007006308-A1 | NOVEL GLUCOPYRANOSE ESTERS AND GLUCOFURANOSE ESTERS OF ALKYL- FU MARATES AND THEIR PHARMACEUTICAL USE | ADITECH PHARMA AB (SE) | 2007-01-18 | — | — | WO | disclosed |
| WO-2006050730-A1 | NOVEL SALTS OF FUMARIC ACID MONOALKYLESTERS AND THEIR PHARMACEUTICAL USE | ADITECH PHARMA AB (SE) | 2006-05-18 | — | — | WO | disclosed |
| WO-2006037342-A2 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING A FUMARIC ACID ESTER | ADITECH PHARMA AB (SE) | 2006-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240240229-A1 | METHODS OF ADMINISTERING MONOMETHYL FUMARATE AND PRODRUGS THEREOF HAVING REDUCED SIDE EFFECTS | GSTM1, GSTM2, GSTA1 | TSHR 4809/4885KDM4E 2062/4885HDAC3 1734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.